Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Neuroderm Ltd. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 pending office actions are handled by 3 distinct examiners. The prosecution activity is spread across 3 distinct art units, which is a count fewer than the 4 pending office actions.
HUI, SAN MING R is the busiest examiner for the company and is responsible for 2 pending office actions. This means HUI, SAN MING R manages a larger portion of the 4 pending office actions than the other examiners. The 3 distinct art units involved suggest that the company's pharmaceutical innovations are being reviewed by that specific number of specialized groups.
Practitioners should be prepared to navigate the requirements of 3 distinct examiners across the 3 distinct art units. The concentration of 2 pending office actions with HUI, SAN MING R indicates that this examiner's style will have a significant impact on the portfolio. The remaining matters are handled by the other distinct examiners within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 2 | 59.6% | +20.0% |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | CHO, DAVID H | 22d |
| 18632667 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | HUI, SAN MING R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | CHO, DAVID H | 22d |
| 18748756 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | HUI, SAN MING R | — |
| 18632667 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1691 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18764647 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE | SHIAO, REI TSANG | 1691 | §103§112DP | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18748756 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | HUI, SAN MING R | 1627 | §102§103DP | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18632667 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | HUI, SAN MING R | 1627 | §101DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | CHO, DAVID H | 1693 | §102§103§112Other | Non-Final OA | 22d | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeuroderm Ltd. has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
San Ming R Hui has the most, with 2 of Neuroderm Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
